Clinical Trials of America Opens New Site
Clinical Trials of America Inc.
has announced the opening of a new Seattle site and named Kathy Hendricks as site manager. Hendricks leads operational and business development and oversees patient recruitment and relations.
“The opening of the Seattle site is the next phase of expansion for Clinical Trials of America,” said President Don Dickerson. “We are leveraging the core strengths of the company’s headquarters in Eugene and building a solid platform beyond Lane County.”
Hendricks brings more than a decade of clinical research and medical assistance experience to her new position and offers a wealth of knowledge to the Clinical Trials of America team. Hendricks has conducted more than 35 clinical trials. She has worked as a clinical research coordinator for research clinics in Washington and North Carolina.
“Her background, training and wide-ranging skill set will be great assets to Clinical Trials of America in the Seattle market,” Dickerson said.
Hendricks can be reached at (206) 769-3175. She reports to Dickerson.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
